Corcept Therapeutics Inc CORT
We take great care to ensure that the data presented and summarized in this overview for CORCEPT THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CORT
View all-
Black Rock Inc. New York, NY16.5MShares$1.22 Billion0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$744 Million0.01% of portfolio
-
Ingalls & Snyder LLC New York, NY8.1MShares$596 Million16.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny6.2MShares$456 Million0.49% of portfolio
-
Parallel Advisors, LLC3.83MShares$282 Million4.44% of portfolio
-
State Street Corp Boston, MA3.55MShares$261 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.08MShares$153 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA2.07MShares$152 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA1.64MShares$121 Million0.07% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ1.38MShares$101 Million0.27% of portfolio
Latest Institutional Activity in CORT
Top Purchases
Top Sells
About CORT
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Insider Transactions at CORT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 11
2025
|
Hazel Hunt Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
85,176
-31.71%
|
$5,791,968
$68.11 P/Share
|
|
Feb 11
2025
|
Hazel Hunt Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+35.84%
|
$450,000
$3.29 P/Share
|
|
Feb 10
2025
|
Daniel N Swisher Jr |
SELL
Open market or private sale
|
Direct |
2,200
-100.0%
|
$149,600
$68.08 P/Share
|
|
Feb 10
2025
|
Daniel N Swisher Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+50.0%
|
$26,400
$12.13 P/Share
|
|
Feb 03
2025
|
Joseph Douglas Lyon |
SELL
Open market or private sale
|
Direct |
5,000
-36.34%
|
$330,000
$66.92 P/Share
|
|
Feb 03
2025
|
Joseph Douglas Lyon |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+16.58%
|
$60,000
$12.46 P/Share
|
|
Feb 03
2025
|
Sean Maduck |
SELL
Open market or private sale
|
Direct |
20,000
-18.99%
|
$1,320,000
$66.92 P/Share
|
|
Feb 03
2025
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+9.02%
|
$80,000
$4.47 P/Share
|
|
Jan 27
2025
|
James N Wilson |
SELL
Bona fide gift
|
Indirect |
7,800
-0.54%
|
-
|
|
Jan 22
2025
|
James N Wilson |
BUY
Other acquisition or disposition
|
Indirect |
146,742
+9.17%
|
-
|
|
Jan 22
2025
|
James N Wilson |
SELL
Bona fide gift
|
Direct |
146,742
-100.0%
|
-
|
|
Jan 22
2025
|
James N Wilson |
SELL
Payment of exercise price or tax liability
|
Direct |
103,258
-41.3%
|
$6,092,222
$59.03 P/Share
|
|
Jan 22
2025
|
James N Wilson |
BUY
Exercise of conversion of derivative security
|
Direct |
250,000
+50.0%
|
$750,000
$3.29 P/Share
|
|
Jan 10
2025
|
Daniel N Swisher Jr |
SELL
Open market or private sale
|
Direct |
2,200
-100.0%
|
$110,000
$50.54 P/Share
|
|
Jan 10
2025
|
Daniel N Swisher Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+50.0%
|
$26,400
$12.13 P/Share
|
|
Jan 03
2025
|
Gary Charles Robb Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,037
+11.59%
|
$9,111
$3.29 P/Share
|
|
Jan 02
2025
|
Sean Maduck |
SELL
Open market or private sale
|
Direct |
20,000
-18.99%
|
$1,000,000
$50.39 P/Share
|
|
Jan 02
2025
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+15.96%
|
$60,000
$3.88 P/Share
|
|
Jan 02
2025
|
Joseph Douglas Lyon |
SELL
Open market or private sale
|
Direct |
5,000
-36.34%
|
$250,000
$50.39 P/Share
|
|
Jan 02
2025
|
Joseph Douglas Lyon |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+26.65%
|
$55,000
$11.35 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 1.3M shares |
|---|---|
| Grant, award, or other acquisition | 19.3K shares |
| Bona fide gift | 2.48K shares |
| Other acquisition or disposition | 175K shares |
| Payment of exercise price or tax liability | 501K shares |
|---|---|
| Bona fide gift | 168K shares |
| Other acquisition or disposition | 36.1K shares |
| Open market or private sale | 338K shares |